Nicotine Dependence Clinical Trial
Official title:
Extended Care for Smoking Cessation Following Psychiatric Hospitalization
Smoking rates among individuals with psychiatric disorders are disproportionately higher than
the general population. The majority of psychiatric hospitals ban smoking on hospital
grounds, thus providing an opportunity for inpatients to experience abstinence. Yet smokers
in inpatient psychiatric settings are infrequently provided with referrals for cessation
treatment on discharge (< 1 %) and most resume smoking upon discharge. Therefore, the
integration of effective cessation interventions within the current mental health treatment
system is a public health priority.
The overall objective of this project is to adapt a Sustained Care (SusC) model to smokers
with severe mental illness (SMI) engaged in a psychiatric hospitalization and to conduct a
randomized, pragmatic effectiveness trial designed to assess the benefit of this adapted SusC
intervention in real-world practice. We will test the hypothesis that, among smokers with SMI
in inpatient psychiatric treatment (n = 422), SusC will result in significantly greater rates
of cotinine-validated, 7-day point prevalence abstinence at 6- and 12-months compared to a
group that receives Usual Care (UC) about smoking cessation. Furthermore, we hypothesize that
a higher proportion of SusC vs. UC patients will use evidence-based smoking cessation
treatment (counseling and pharmacotherapy) in the month after discharge. We will also explore
the effect of SusC on health and health care utilization in the 12 months post-discharge
(psychiatric symptoms, psychiatric and medical hospital readmissions and emergency room
visits) and the effectiveness of SusC on smoking abstinence in patient diagnostic subgroups.
The expected outcome of this project is a demonstration of the effectiveness of a Sustained
Care intervention for smoking cessation in individuals with severe mental illness (SMI)
following psychiatric hospitalization. Future studies could extend these findings to
individuals with SMI receiving outpatient psychiatric treatment or psychotherapy. Overall,
this research would have a significant positive public health impact that will move us closer
to the long-term goal of dissemination and integration of the Sustained Care model to
increase smoking cessation and decrease smoking related morbidity and mortality in people
with severe mental illness.
Status | Recruiting |
Enrollment | 422 |
Est. completion date | June 2019 |
Est. primary completion date | June 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - >18 years of age - current smoker (i.e., at least 5 cigarettes/day when not hospitalized) Exclusion Criteria: - current diagnosis of dementia - Mini-Mental State Examination (MMSE: [45]) score < 24 - patient's inability to provide consent for study participation due to his/her inability to demonstrate an understanding of study procedures as contained in the statement of informed consent, after no more than two explanations - current diagnosis of mental retardation or autistic disorder - current primary diagnosis of a (non-nicotine) substance use disorder - no access to a telephone or inability to communicate by telephone - no planned discharge to institutional setting - medical contraindication for the use of nicotine replacement therapy (NRT) - pregnancy, breastfeeding, or plans to become pregnant within 6 months. |
Country | Name | City | State |
---|---|---|---|
United States | Seton Shoal Creek Hospital | Austin | Texas |
Lead Sponsor | Collaborator |
---|---|
University of Texas at Austin | National Institute of Mental Health (NIMH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Incremental cost effectiveness | 6 month | ||
Other | Psychiatric symptoms | 6 months | ||
Other | Hospital readmissions, both psychiatric and medical | 6 months | ||
Other | Emergency room visits, both psychiatric and medical | 6 months | ||
Primary | Biochemically verified smoking abstinence via saliva cotinine | 6 months | ||
Secondary | Proportion of patients who use smoking cessation medication or counseling following discharge | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05176418 -
IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate
|
Early Phase 1 | |
Completed |
NCT04084210 -
Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use
|
Phase 2 | |
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Withdrawn |
NCT03707600 -
State and Trait Mediated Response to TMS in Substance Use Disorder
|
N/A | |
Recruiting |
NCT03999099 -
Targeting Orexin to Treat Nicotine Dependence
|
Phase 1 | |
Completed |
NCT03847155 -
Prevention of Nicotine Abstinence in Critically Ill Patients After Major Surgery
|
N/A | |
Completed |
NCT02840435 -
Study on Sit to Quit Phone Intervention
|
N/A | |
Completed |
NCT02139930 -
Project 2: Strategies for Reducing Nicotine Content in Cigarettes
|
N/A | |
Completed |
NCT01926626 -
Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers
|
Phase 2 | |
Completed |
NCT01982110 -
A Mindfulness Based Application for Smoking Cessation
|
N/A | |
Completed |
NCT01569490 -
Striving to Quit: First Breath
|
N/A | |
Completed |
NCT01632189 -
The Effect of Varenicline on D2/D3 Receptor Binding in Smokers
|
N/A | |
Completed |
NCT01685996 -
Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01569477 -
Striving to Quit-Wisconsin Tobacco Quit Line
|
N/A | |
Active, not recruiting |
NCT01182766 -
New Treatment for Alcohol and Nicotine Dependence
|
Phase 2/Phase 3 | |
Completed |
NCT01061528 -
Coping Skills Treatment for Smoking Cessation
|
N/A | |
Completed |
NCT00996034 -
Nicotine Vaccination and Nicotinic Receptor Occupancy
|
Phase 2 | |
Completed |
NCT01943994 -
Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study
|
N/A | |
Suspended |
NCT01636336 -
Effects of Progesterone on Smoked Nicotine Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effects
|
N/A | |
Withdrawn |
NCT01589081 -
Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect
|
N/A |